Liam Condon buys 10 JMAT shares while chemicals stay choppy

Johnson Matthey Johnson Matthey Plc sits in a part of the market that has not exactly been rewarded for patience. European chemicals are still working through a fragile recovery, and the sector has been split between names that can show pricing power and names that are still waiting for volume to catch up. BASF has been the useful comparison point here, because it has been able to point to higher second-quarter earnings in 2026 on better prices and volumes in several segments, while also leaning on cost discipline and buybacks. That is the kind of backdrop that makes every corporate action at a peer worth reading carefully, even when the action itself is small.

Johnson Matthey has its own moving parts. The company completed the sale of its Catalyst Technologies business to Honeywell for an enterprise value of £1.325 billion, which matters more than any routine director purchase because it changes the shape of the business and the cash it can deploy. The shares were trading near 2,190 to 2,200 GBX in mid-August 2026, with analysts' average 12-month target at 2,283 GBX across six covering firms. That is not a screaming discount, but it is also not a market that has fully priced in a clean rerating. You can see why a cluster of director buys, even through a monthly plan, gets attention.

Why the business case comes before the filing

The best argument for Johnson Matthey begins with the fact that this is not a one-note industrial. It has exposure to platinum group metals markets, it operates in specialty chemicals, and it has just taken a meaningful step in reshaping the portfolio by selling Catalyst Technologies. That kind of move can do two things at once. It can simplify the story for the market, and it can leave management with more room to decide where capital should go next. If you are looking for a reason the stock could still work from here, that is the place to start.

The sector backdrop helps that case, at least a little. UK markets were under pressure in the week to 14 August 2026, with the FTSE 100 down around 1.1% to 1.4% to roughly 10,750 points, while the Bank of England held Bank Rate at 3.75% and pointed to risks from elevated and volatile energy prices tied to Middle East developments. At the same time, UK GDP grew 0.4% in the second quarter. That mix is awkward for cyclicals, but it is not a recession tape. For a company like Johnson Matthey, which has to live with both industrial demand and commodity-linked inputs, the difference matters.

The insider action fits that constructive frame in a limited way. On 11 August 2026, Condon acquired 10 ordinary shares at £21.92565 each for £219.26, while Chief Financial Officer Alastair Judge and Chief Operating Officer Richard Pike each acquired 12 shares at the same price for £263.11 apiece. The transactions were notified on 13 August and took place on the London Stock Exchange through the Share Incentive Plan. This is not a grand gesture. It is a monthly plan buy. Still, the direction is the direction, and all three named executives bought rather than sold.

The pattern matters more than the size. InsiderTrades data flags the filing as a cluster, and it is not hard to see why. Three distinct insiders bought, and the recent declaration history shows repeated buys from the same trio on 13 August and again on 16 August. Our scoring gives the name a 43, helped by the chief executive role, the cluster, and a euro-normalised filing value near EUR 120. That score is not the thesis. It is just a compact way of saying the same thing the filing already says in plain English, which is that the boardroom did not use this window to lighten up.

Why the comparison set matters more than the headline

Johnson Matthey does not trade in a vacuum. BASF is the obvious large-cap chemical comparator because it has been able to talk about improved earnings and disciplined capital allocation while the broader sector still looks uneven. Croda International has also been used in sector commentary as a comparator in specialty chemicals, which is useful because it reminds you that the market is still sorting winners by quality of earnings, not by size alone. Johnson Matthey has to earn its multiple in that company.

That is where the recent portfolio move becomes relevant. Selling Catalyst Technologies to Honeywell for £1.325 billion gives the market a cleaner lens on the remaining business, but it also removes a source of complexity that may have obscured the underlying operating picture. If management can show that the remaining mix deserves a better valuation, the market has a reason to listen. If it cannot, the sale just becomes a cash event. The insider buys do not answer that question, but they do tell you the top of the house is willing to keep adding exposure while the story resets.

The share price context is not trivial either. JMAT near 2,190 to 2,200 GBX with a 2,283 GBX average target across six analysts leaves some room, but not much. That is a market that is already giving some credit for the restructuring and the sector backdrop. You are not buying a broken chart and a blank slate. You are buying a name that has already had some of the good news reflected in it, which makes the quality of the next operational update more important than the existence of the insider filing.

Why the filing is tiny and the business is not

The first thing to say about these purchases is that they are routine. They came through the Share Incentive Plan, they were small in cash terms, and they were not open-market block buys. Condon's purchase was worth £219.26, or about EUR 120 on the platform's euro-normalised basis. Judge and Pike each bought for £263.11, or about EUR 143.47. Those are not the numbers of someone making a loud statement about undervaluation. They are the numbers of executives participating in a plan that runs on a schedule.

That is where the honest read starts to narrow. A cluster is useful, but it is not magic. The fact that three directors bought in the same window tells you the company is not in a mood to signal caution from the top, yet the size of the transactions tells you very little about how they see the next quarter, the next half, or the next year. If you want to make too much of this, the data will let you. It should not.

Our cohort data is the right place to keep that discipline. For chief-executive buys at large-cap names, the historical 90-day win rate is 58.4%, with an average 90-day return of 5.42% and an average 365-day return of 42.87%. That is a decent historical bucket, and it is better than random noise, but it is still just a bucket. It does not turn a small SIP buy into a forecast. It does not tell you that Johnson Matthey will follow the average. It tells you that this kind of filing has, in the past, been associated with a mildly favorable short-term outcome more often than not.

The balance sheet of evidence is still mixed

Johnson Matthey's fundamental score in InsiderTrades data is 37, with a rank of 20,658 out of 28,434. That is not a disaster, but it is not the kind of internal backdrop that lets you ignore the operating work ahead. The value score is 52 and the quality score is 21, which is a neat way of saying the market may be giving some credit to the asset base and the strategic reset, while still doubting the consistency of the underlying economics. Growth is not available in the dossier, so there is no point pretending otherwise.

That mix matters because insider buying is easiest to overread when the business itself is already improving. Here, the business is in transition. The sale of Catalyst Technologies helps, but it does not solve the question of what the remaining portfolio can earn through a cycle. The PGM exposure can help when industrial demand and pricing cooperate, and it can hurt when they do not. That is the real risk, not the optics of a few shares bought under a plan.

The macro backdrop adds another layer. The Bank of England is still holding rates at 3.75%, energy prices remain volatile, and the FTSE 100 has been soft. For a UK-listed industrial with global exposure, that is not a friendly combination. It does not break the case, but it does mean the market will demand proof, not narrative. If Johnson Matthey can show cleaner earnings after the portfolio sale, the stock has room to work. If not, the insider cluster will look like what it probably is, a routine expression of alignment rather than a decisive tell.

What the repeated buys say about the boardroom mood

The recent declaration history is the most interesting part of the filing set. InsiderTrades data shows 12 recent declarations in the cluster view, with buys from Condon, Judge and Pike on 13 August and again on 16 August. That repetition is more useful than the individual share counts because it shows the same names returning to the market on more than one date. It is not a one-off checkbox exercise. It is a pattern of participation.

Still, the pattern sits inside a narrow frame. These are director-level filings at a large-cap name, and the amounts are tiny relative to the company's roughly EUR 3.23 billion market cap. The chief executive's purchase is the most informative because our scoring weights that role most heavily, but even there the euro-normalised value is near EUR 120. You do not need to romanticize that. The better interpretation is simpler. Management is buying into the stock on schedule while the company is in the middle of a strategic reset and the sector is still uneven.

That is enough to keep the name on a watchlist. It is not enough to make the stock obvious. The market has already given Johnson Matthey some credit for the sale of Catalyst Technologies and for the possibility of a cleaner future mix. The insider cluster says the top table is not stepping away from that story. The next real test is whether the remaining business can show the kind of operating progress that makes the sale look like a beginning rather than a one-time event.

The cautious read on Johnson Matthey now

If you want the bullish version, it is straightforward. Johnson Matthey has simplified its portfolio, the shares are not priced like a deep distress case, the sector is showing signs of life in places, and three senior executives bought through the SIP in the same window. Our data also gives chief-executive buys at large-cap names a respectable historical 90-day profile, which is enough to keep the filing from being dismissed as pure noise.

If you want the catch, it is equally straightforward. The buys are tiny, the plan is routine, the business is still exposed to a cyclical and commodity-linked backdrop, and the fundamental score is middling rather than strong. The market is not asking whether insiders like their own stock. It is asking whether the post-sale Johnson Matthey can produce cleaner returns and a better earnings profile than the one it just sold off. The filing does not answer that.

So the balanced verdict is not elegant, and it should not be. The cluster is a useful confirmation that management is still aligned with the equity while the company resets. It is not a reason to chase the shares on its own. If you own the name, the next thing that matters is the first set of numbers that show what the remaining portfolio can do after the Catalyst Technologies sale, and whether the market keeps the stock near the 2,190 to 2,200 GBX area or starts to test the 2,283 GBX analyst target.

Dig deeper: Liam Condon's filing track record.

This is not investment advice.